CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...
Phase 1
Nashville, Tennessee, United States and 65 other locations
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food rest...
Nashville, Tennessee, United States and 11 other locations
and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic...
Phase 1
Nashville, Tennessee, United States and 17 other locations
compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive ...
Phase 2
Nashville, Tennessee, United States and 35 other locations
or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...
Phase 2, Phase 3
Nashville, Tennessee, United States and 91 other locations
evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors...
Phase 2
Nashville, Tennessee, United States and 21 other locations
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma whic...
Phase 3
Nashville, Tennessee, United States and 40 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Nashville, Tennessee, United States and 15 other locations
This study is open to adults with advanced pancreatic cancer for whom previous treatment was not successful or no treatment exists. ...
Phase 1
Nashville, Tennessee, United States and 11 other locations
(with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzaluta...
Phase 1, Phase 2
Nashville, Tennessee, United States and 30 other locations
Clinical trials
Research sites
Resources
Legal